of Tasmania, Quality: Q1 intervention Exclusion: Hobart, Australia group) Previous BMD measurement, thyroid disease, renal failure, malignancy, rheumatoid arthritis, history of hysterectomy, HRT, pregnancy, lactating BMD = bone mineral density/densitometry; DXA = dual X-ray absorptiometry; HRT = hormone replacement therapy; SD = standard deviation Table 38 Systematic review included to address the safety and effectiveness of DXA testing in women aged 50 years Study Study design / Quality Study population Selection criteria Studies included Findings appraisal Nelson et al. () Systematic review to Men aged 50 years or RCTs of screening or medications Direct evidence: No studies were identified determine the effectiveness older and with fracture outcomes published No trials were identified and harms of osteoporosis postmenopausal women in English, performance studies of screening in reducing aged 60 years or older; validated risk-assessment Safety: fractures for men and 60–64 years at increased instruments, and systematic No trials were identified women without risk for osteoporotic reviews and population-based known previous fractures; fractures; 60–64 years not studies of BMD tests or the performance of risk at increased risk for medication harms assessment instruments osteoporotic fractures; and bone measurement and 65 years or older tests in identifying persons with osteoporosis, optimal screening intervals, and efficacy and harms of medications to reduce primary fractures Although the risk of bias of included studies was poorly
of Tasmania, Hobart, Australia Quality: Q1 intervention group) Exclusion: Previous BMD measurement, thyroid disease, renal failure, malignancy, rheumatoid arthritis, history of hysterectomy, HRT, pregnancy, lactating BMD = bone mineral density/densitometry; DXA = dual X-ray absorptiometry; HRT = hormone replacement therapy; SD = standard deviation Table 38 Systematic review included to address the safety and effectiveness of DXA testing in women aged 50 years Study Study design / Quality appraisal Study population Selection criteria Studies included Findings Nelson et al. () Systematic review to determine the effectiveness and harms of osteoporosis screening in reducing fractures for men and women without known previous fractures; the performance of risk assessment instruments and bone measurement tests in identifying persons with osteoporosis, optimal screening intervals, and efficacy and harms of medications to reduce primary fractures Although the risk of bias of included studies was poorly Men aged 50 years or older and postmenopausal women aged 60 years or older; 60–64 years at increased risk for osteoporotic fractures; 60–64 years not at increased risk for osteoporotic fractures; and 65 years or older RCTs of screening or medications with fracture outcomes published in English, performance studies of validated risk-assessment instruments, and systematic reviews and population-based studies of BMD tests or medication harms Direct evidence: No trials were identified Safety: No trials were identified No studies were identified